ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.
Tela Bio, a US-based surgical reconstruction technology developer backed by healthcare provider ProMedica and pharmaceutical firm Pacira Pharmaceuticals, filed on Tuesday to raise up to $69m in its initial public offering.
Founded in 2012, Tela Bio provides soft tissue reinforcement materials for hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its implants have been used by more than 6,500 patients to date.
The company has raised approximately $106m in equity funding in total, according to press releases…
